We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest’s Substack. In ...

Regeneron stock just slipped on a banana peel, hitting a 52-week low at $493.15 before closing at $496.06. Despite this dip, ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron Pharmaceuticals saw a downgrade from Wells Fargo, slicing its stock rating from "overweight" to "equal weight" and ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to Sector Perform from Outperform, ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

NanoViricides (NNVC) is presenting at the prestigious BIO International Convention on June 16th, showcasing their revolutionary broad-spectrum antiviral platform that could transform how we treat ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

Is Regeneron a good stock to buy now in light of a potential 23andMe acquisition? Here's a quick look at what it's paying for to find out. 23andMe's market cap peaked at $5.8 billion a few months ...